|
⚲
|
| Keyboard |
| Perceptive Advisors LLC
✚
|
|
|---|---|
| CRD # | 154703 |
| SEC # | 801-71841 |
| CIK # | 0001224962 |
| AUM | 11.77 B (2026-03-30) |
| Employees | 49 (57% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 646-205-5300 |
| Address | 51 Astor Place New York, NY 10003 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| In the News | |
|---|---|
| Thu, 30 Jul 2026 | Perceptive Advisors LLC Initiates a Major Stake in Perceptive Ca — GuruFocus |
| Fri, 10 Jul 2026 | LeonaBio (LONA) awards 28,000 stock options tied to Perceptive Advisors board role — Stock Titan |
| Tue, 07 Apr 2026 | Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors — Yahoo Finance |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Praxis Precision Medicines Inc | 0.7 | ||
| Celcuity Inc | 0.4 | ||
| Ascendis Pharma A/S | 0.4 | ||
| Roivant Sciences Ltd | 0.2 | ||
| Rhythm Pharmaceuticals Inc | 0.2 | ||
| Aeglea Biotherapeutics Inc | 0.2 | ||
| Nuvalent Inc | 0.2 | ||
| Edgewise Therapeutics Inc | 0.1 | ||
| Protagonist Therapeutics Inc | 0.1 | ||
| Apogee Therapeutics Inc | 0.1 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Perceptive Credit Opportunities Fund V LP | [2026-02-23] | 677.8 M | |
| Filed 2025-10-29 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Perceptive SP G LP | 2025-03-26 | 7.2 M | |
| Other | PCOF Phoenix II AIV III LP | 2024-03-28 | 1.2 M | |
| PE | Perceptive Capital Solutions Fund A LP | [2024-03-28] | 5.6 M | 62.1 M |
| Filed 2025-02-04 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Not Applicable | ||||
| PE | Perceptive Capital Solutions Fund LP | [2024-03-28] | 218.8 M | 364.4 M |
| Filed 2025-02-04 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Not Applicable | ||||
| PE | PX Venture C LLC | [2024-03-20] | 5.1 M | |
| Filed 2023-07-18 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| Other | PCOF EQ AIV IV LP | 2022-03-31 | 3.3 M | |
| HF | Perceptive Credit Opportunities Fund IV LP | [2022-03-31] | 1,495.1 M | |
| Filed 2022-07-21 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Not Applicable | ||||
| PE | Perceptive SP C LP | 2022-03-31 | 3.9 M | |
| PE | Perceptive SP D LP | 2022-03-31 | 2.7 M | |
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 25 | 11.7 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 1 | 0.1 |
| Total | 26 | 11.8 |
| By Discretionary | ||
| Discretionary | 26 | 11.8 |
| Non-Discretionary | 0 | 0.0 |
| Total | 26 | 11.8 |
| By Non-United States Persons | ||
| Non-United States Persons | 4.6 | |
| United States Persons | 7.1 | |
| Total | 26 | 11.8 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Scott Dakers | Director | 141 | 35 | |
| Ernest Morrison | Director | 27 | 11 | |
| Joseph Edelman | Director, Executive Officer | 35 | 2 | |
| Perceptive Credit Opportunities GP LLC | Director, Executive Officer | 19 | 2 | |
| Perceptive Xontogeny Venture GP LLC | Executive Officer | 4 | 2 | |
| Perceptive Discovery GP LLC | Executive Officer | 3 | 2 | |
| Lev LB Holdings GP LLC | Executive Officer | 1 | 1 | |
| Perceptive LS GP LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001224962] | |
| 3 | [0001224962] | |
| 4 | [0001224962] | |
| SC 13D | [0001224962] | |
| SC 13G | [0001224962] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $1.9B |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 54930051M1DQYADROP30 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Solid Biosciences Inc SLDB
Pre-Funded Warrant (right to buy) · derivative
|
2026-03-09 | Grant | 8,912,655 | $5.61 | 49,999,995 |
|
MeiraGTx Holdings PLC MGTX
Ordinary Shares
|
2025-12-31 | Disposed to issuer | 2,300,000 | $7.91 | 18,193,000 |
|
LeonaBio Inc ATHA
Series A Warrant (right to buy) · derivative
|
2025-12-23 | Grant | 1,279,526 | $6.35 | 8,124,990 |
|
LeonaBio Inc ATHA
Pre-Funded Warrant (right to buy) · derivative
|
2025-12-23 | Grant | 1,372,935 | $6.35 | 8,718,137 |
|
LeonaBio Inc ATHA
Series B Warrant (right to buy) · derivative
|
2025-12-23 | Grant | 3,543,307 | $6.35 | 22,499,999 |
|
LeonaBio Inc ATHA
Common Stock
|
2025-12-23 | Grant | 329,756 | $6.35 | 2,093,951 |
|
LeonaBio Inc ATHA
Pre-Funded Warrant (right to buy) · derivative
|
2025-12-23 | Grant | 457,645 | $6.35 | 2,906,046 |
|
LeonaBio Inc ATHA
Series B Warrant (right to buy) · derivative
|
2025-12-23 | Grant | 1,181,101 | $6.35 | 7,499,991 |
|
LeonaBio Inc ATHA
Common Stock
|
2025-12-23 | Grant | 989,270 | $6.35 | 6,281,864 |
|
LeonaBio Inc ATHA
Pre-Funded Warrant (right to buy) · derivative
|
2025-12-23 | Grant | 5,502,402 | ||
|
LeonaBio Inc ATHA
Series A Warrant (right to buy) · derivative
|
2025-12-23 | Grant | 3,838,583 | $6.35 | 24,375,002 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2025-11-13 | Sell | 3,213 | $3.90 | 12,531 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2025-11-13 | Sell | 28,597 | $3.90 | 111,528 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2025-11-12 | Sell | 7,862 | $4.06 | 31,920 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2025-11-12 | Sell | 883 | $4.06 | 3,585 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2025-11-11 | Sell | 537 | $4.31 | 2,314 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2025-11-11 | Sell | 4,783 | $4.31 | 20,615 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2025-11-10 | Sell | 16,633 | $4.54 | 75,514 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2025-11-10 | Sell | 1,869 | $4.54 | 8,485 |
|
Lyra Therapeutics Inc LYRA
Common Stock
|
2025-11-07 | Sell | 17,746 | $4.75 | 84,294 |
| showing 20 of 200 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
BSP CLO Management LLC
✚
|
NY | 12.24 B |
|
Pacific Private Fund Advisors LLC
✚
|
CA | 12.24 B |
|
Canyon Capital Advisors LLC
✚
|
TX | 11.92 B |
|
Levine Leichtman Capital Partners LLC
✚
|
CA | 11.88 B |
|
Paradigm Operations LP
✚
|
CA | 11.87 B |
|
Entrust Global Partners LLC
✚
|
NY | 11.82 B |
|
TPG Solutions Advisors LLC
✚
|
TX | 11.61 B |
|
One William Street Capital Management LP
✚
|
NY | 11.30 B |
|
Guggenheim Corporate Funding LLC
✚
|
NY | 11.29 B |
|
Orchard Global Asset Management LLP
✚
|
11.28 B |